Reversible inactivation of cytochrome P450 by alkaline earth metal ions: auxiliary metal ion induced conformation change and formation of inactive P420 species in CYP101.
The effects of the divalent alkaline-earth metal ions (Ca2+ and Mg2+) on the substrate binding affinity, spin-state transition at the heme active site, conformational properties as well as the stability of the active form of cytochrome P450cam (CYP 101) have been investigated using various spectroscopic and kinetic methods. The divalent cations were found to have two types of effects on the enzyme. At the initial stage the alkaline-earth metal ion facilitated enhanced binding of the substrate and formation of the high-spin form of the heme active center of the enzyme compared to that in absence of any metal ion. However, analogous to many other mono-valent metal ions, the alkaline-earth metal ions were also less efficient than K+ in promoting the substrate binding and spin-transition properties of the enzyme. The auxiliary metal ions were shown to cause small but distinct change in the circular dichroism spectra of the substrate-free enzyme in the visible region, indicating that the tertiary structure around the heme was perturbed on binding of the auxiliary metal ion to the enzyme. The effect of the auxiliary metal ion was found to be more prominent in the WT enzyme compared to the Y96F mutant of P450cam suggesting that the Tyr 96 residue plays an important role in mediating the effects of the auxiliary metal ions to the active site of the enzyme. At the second stage of interaction, the alkaline-earth metal ions were found to slowly convert the enzyme into an inactive P420 form, which could be reversibly re-activated by addition of KCl. The results have been discussed in the light of understanding the mechanism of inactivation of certain mammalian P450 enzymes by these alkaline-earth metal ions.
Manna
Soumen K
SK
Department of Chemical Sciences, Tata Institute of Fundamental Research, Homi Bhabha Road, Colaba, Mumbai 400 005, India.
Mazumdar
Shyamalava
S
D002118:Calcium / Q000494:pharmacology*; D002164:Camphor / Q000494:pharmacology; D019475:Camphor 5-Monooxygenase / Q000037:antagonists & inhibitors* / Q000737:chemistry; D002413:Cations, Divalent / Q000494:pharmacology*; D002942:Circular Dichroism; D065607:Cytochrome P-450 Enzyme Inhibitors; D008274:Magnesium / Q000494:pharmacology*; D011189:Potassium Chloride / Q000494:pharmacology; D013056:Spectrophotometry, Ultraviolet
D002413:Cations, Divalent; D065607:Cytochrome P-450 Enzyme Inhibitors; D011189:Potassium Chloride; D002164:Camphor; D019475:Camphor 5-Monooxygenase; C102512:cytochrome P420(cam); D008274:Magnesium; D002118:Calcium